GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » Net Change in Cash

Ikena Oncology (Ikena Oncology) Net Change in Cash : $23.93 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ikena Oncology Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Ikena Oncology's Net Change in Cash for the three months ended in Mar. 2024 was $-67.04 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $23.93 Mil.

Ikena Oncology Net Change in Cash Historical Data

The historical data trend for Ikena Oncology's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ikena Oncology Net Change in Cash Chart

Ikena Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
63.93 81.28 69.73 -172.30 60.38

Ikena Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.59 41.54 50.82 -1.38 -67.04

Ikena Oncology Net Change in Cash Calculation

Ikena Oncology's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-79.743+64.144+75.98+0
=60.38

Ikena Oncology's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-18.304+-48.738+0+0
=-67.04

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ikena Oncology Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Ikena Oncology's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Ikena Oncology (Ikena Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » Net Change in Cash
Comparable Companies
INZY SELB DNTH CBUS PSTX MACK STOK ALVR TCRX ATXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
645 Summer Street, Suite 101, Boston, MA, USA, 02210
Website
https://www.ikenaoncology.com
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.
Executives
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Jotin Marango officer: CFO & Head of Corp. Dev. C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Francisco Oliveira officer: Principal Accounting Officer IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210
Richard Wooster director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Xiaoyan Michelle Zhang officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Maria Koehler director C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mark Manfredi director, officer: President & CEO C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Maude Tessier officer: Chief Business Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey Ecsedy officer: Chief Scientific Officer C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139